✉news BusinessRetail first seen 16 h ago, last 15 h ago, peak #24
Ultragenyx Sells FDA Priority Review Voucher for $210 Million
Original: Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity
Ultragenyx has agreed to sell an FDA priority review voucher for $210 million, giving the buyer an expedited review path for a future drug application. The deal provides a cash boost for the biotech, which is focused on rare disease therapies. Retail investors are calling it a significant buying opportunity, arguing the proceeds strengthen Ultragenyx's balance sheet at a time when small-cap biotechs face tight funding conditions. The sale highlights the ongoing market value of priority review vouchers.
Why now: The sizable cash infusion and bullish retail reaction are drawing attention to Ultragenyx's stock.
Rank over time, top of the chart is #1. 2 snapshots from 16 h ago to 15 h ago.
Evidence
- Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity · TradingView
- Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity · Stocktwits
API: https://socialmediatrends-api.osmike.com/v1/trends/1378581